Founded in 2001 and headquartered in Cologne, Germany, Axiogensis is one of a small number of companies specializing in induced pluripotent stem cell (iPSC) products. The company also has an American subsidiary that was founded in 2014 and is located in Philadelphia, Pennsylvania. Since its launch, the company has grown into a market leader for in vitro models of healthy and diseased cell types and tissue. [Read more…]
Cynata Announces Japanese Patent Office to Grant Patent for Cymerus™ MSC Technology
Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news today that the Japanese Patent Office will grant a patent for its unique Cymerus™ MSC technology.
To learn more, read the full press release from Cynata Therapeutics, included below with permission Dr. Ross Macdonald, CEO of Cynata Therapeutics.
Cynata Announces Japanese Patent Office Decision to Grant Patent for Cymerus™ MSC Technology
Melbourne, Australia; 2 May 2016 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced that the Japanese Patent and Trademark Office has issued a Decision to Grant a patent covering certain aspects of its proprietary Cymerus™ mesenchymal stem cell (MSC) manufacturing technology. [Read more…]
Lonza Reports Strong First Quarter in History in Terms of Sales and Earnings
The possibilities arising from stem cells have resulted in great commercial interest, with potential applications ranging from their use in the reversal of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, toxicology assessment, and more. To facilitate research resulting from interest in these potential far-ranging applications, a large and growing stem cells research products market has emerged.
One of several large companies selling stem cell research products is Lonza Group. Others competitors include Thermo Fisher Scientific, BD Biosciences, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Clontech (a Takara Bio Company), GE Healthcare Life Sciences, and more.
In major news released today, Lonza Group from Basel, Switzerland, reported a record 1st quarter of 2016, recording its “strongest first quarter in history in terms of sales and earnings.”
Lonza has several different business divisions, including Pharma&Biotech, Specialty Ingredients, Custom Manufacturing, and more. One of these divisions is Lonza Bioscience (LBS), which develops and manufactures tools for life sciences researchers. In this April 26, 2016, press release, Lonza states: “Our healthy Bioscience Solutions business showed further improvement compared with the previous year, driven by product introductions and sound demand in all sub-segments.”
To learn more about Lonza’s role within the research products market, view “Stem Cell Research Products – Opportunities, Tools, and Technologies.
To learn more about Lonza’s record first quarter results, read the full press release issued by Lonza Group (below). [Read more…]
Cynata Ripe for Global Partnerships as Patent for Cymerus™ MSC Technology Gets Approval in Japan
Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news today that the Japanese Patent Office will grant a patent for its unique Cymerus™ MSC technology.
Titled “Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-free Conditions,” the patent covers a proprietary method for deriving MSCs from pluripotent stem cells, to which Cynata Therapeutics with commercial rights in Japan through 2031. [Read more…]
What is the Future of BioInformant?
As BioInformant has grown more and more prominent within the stem cell marketplace, I am often asked about my vision for BioInformant.com and what the future will hold for our company.
Without question, my vision is to grow BioInformant.com into the largest, highest-quality provider of stem cell industry news in the world.
More specifically, I want to see BioInformant.com readership near 500,000 views per month by the end of 2017. [Read more…]
- « Previous Page
- 1
- …
- 162
- 163
- 164
- 165
- 166
- …
- 200
- Next Page »